Replies to post #133751 on Biotech Values

[DewDiligence]

To now argue that MNTA is equally valuable to a buyer does not follow. Some of that value has now flowed to Baxter.

I would submit that you’re having a brain cramp.

Pursuant to the partnership with MNTA, BAX derives economic benefits and BAX is paying MNTA in the form of up-front cash, milestones, and royalties for those derived benefits. If the price being paid by BAX is fair, MNTA is not any more or less valuable as a corporate entity today than it was yesterday.